Differential Interactions Between Chlordiazepoxide, Pentobarbital and Benzodiazepine Antagonists Ro 15-1788 and CGS 8216 in a Drug Discrimination Procedure
Overview
Pharmacology
Psychology
Social Sciences
Authors
Affiliations
Rats were trained to discriminate either chlordiazepoxide (CDP, 4 mg/kg, IP, N = 8) or pentobarbital (PB, 10 mg/kg, IP, N = 8) from saline in a two-lever food-reinforced procedure. CDP and PB dose-dependently substituted for each other (greater than or equal to 90% drug lever responses); indicating that their discriminative stimulus properties were closely similar. However, discriminative stimulus control induced by CDP and PB differentially was affected by the proposed benzodiazepine (BDZ) antagonists Ro 15-1788 (0.08-20 mg/kg, IP) and CGS 8216 (2.5-20 mg/kg, IP) in each experimental group; suggesting that the discriminative stimulus properties of CDP and PB are mediated by different mechanisms of action. When administered alone, Ro 15-1788 (5 and 20 mg/kg), but not CGS 8216, induced CDP like discriminative effects, suggesting that Ro 15-1788 may have partial (BDZ like) agonist properties, not shown by CGS 8216. Additional evidence for a behavioral difference between Ro 15-1788 and CGS 8216 is suggested by differential effects of both compounds on response rate. The results may reflect differential interactions of the compounds with the BDZ receptor-GABA receptor-Cl- ionophore complex.
Carisoprodol tolerance and precipitated withdrawal.
Gatch M, Nguyen J, Carbonaro T, Forster M Drug Alcohol Depend. 2011; 123(1-3):29-34.
PMID: 22055010 PMC: 3288484. DOI: 10.1016/j.drugalcdep.2011.10.010.
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.
Gonzalez L, Gatch M, Taylor C, Bell-Horner C, Forster M, Dillon G J Pharmacol Exp Ther. 2009; 329(2):827-37.
PMID: 19244096 PMC: 2672873. DOI: 10.1124/jpet.109.151142.
Discriminative stimulus effects of melatonin in the rat.
Levesque T, Locke K Psychopharmacology (Berl). 1994; 116(2):167-72.
PMID: 7862946 DOI: 10.1007/BF02245059.
De Vry J, Slangen J Psychopharmacology (Berl). 1986; 88(3):341-5.
PMID: 3083454 DOI: 10.1007/BF00180836.
De Vry J, Slangen J Psychopharmacology (Berl). 1986; 88(2):177-83.
PMID: 3006110 DOI: 10.1007/BF00652236.